BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds  HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting CXCR2 could treat androgen receptor antagonist-resistant prostate cancer. Knockout of CXCR2, which is found on treatment-resistant, androgen receptor-negative neuroendocrine tumor cells in heterogeneous prostate cancers, restored sensitivity to...
BC Extra | Dec 18, 2019
Company News

Dec. 18 Company Quick Takes: FDA approves enfortumab vedotin; plus ODAC roundup, Illumina-PacBio, Benlysta, Ultragenyx, Syros-GBT, Xtandi

Enfortumab vedotin approved for urothelial cancer FDA granted accelerated approval to Padcev enfortumab vedotin-ejfv from Seattle Genetics Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (Tokyo:4503) to treat locally advanced or metastatic urothelial cancer in adults who...
BC Extra | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

GBT's sickle cell therapy snags accelerated approval  FDA granted accelerated approval to Oxbryta voxelotor from Global Blood Therapeutics Inc. (NASDAQ:GBT) to treat sickle cell disease three months ahead of its Feb. 26 PDUFA date, marking...
BioCentury | Oct 28, 2019

Nuvation Bio taking multimechanism approach with $275M series A

Nuvation’s lead investor believes the experience of its management team and its multitarget approach to oncology will be key differentiators as the start-up maps out a plan to deploy its $275 million series A round....
BC Extra | Sep 30, 2019
Clinical News

Dual ESMO readouts could expand Lynparza's reach to new patients

In a pair of wins for Lynparza, new data presented at ESMO showed the PARP inhibitor led to survival benefits in both a biomarker-selected group of prostate cancer patients and a combination with Avastin to...
BC Extra | Aug 22, 2019
Company News

Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

GSK seeking approval of HIF-PH inhibitor in Japan  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it submitted an NDA to Japan's Ministry of Health, Labour and Welfare for daprodustat to treat patients with renal anemia due to...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BC Extra | Aug 7, 2019
Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

Waylivra hits Phase II/III endpoint in FPL  Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said Waylivra volanesorsen cut serum triglyceride levels by 88% vs. 22% for placebo (p<0.001) in patients with familial partial...
Items per page:
1 - 10 of 361